Home
At a glance
Contact us
Home
»
Media
»
Press Releases
Debio 0617
Date
Article Title
13 Sep 2010
Debiopharm Group™ and Aurigene nominate development candidate
20 Nov 2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
13 Jul 2006
Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets
Latest News
15 May 2012
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis
16 February 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
09 November 2011
Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease
About us
Our business
Responsibility
Careers
Media
Press Releases
Publications
Download center
Events
Debiopharm on
Legal Notice
CSOnline
Credits
Sitemap
© 2012 Debiopharm Group
